Zimmer Biomet Holdings (ZBH) Stock

Zimmer Biomet Holdings (ZBH) is broadening its range of products and enhancing its cash flow, setting itself up for lasting profits and financial stability. Compared to its competitors, ZBH is undervalued and has great growth potential due to its focus on innovation, acquisitions, and better operational efficiency. The company's emphasis on high-growth markets and improving profit measures suggests a positive future, even though it has not performed well in the past.

Zimmer Biomet is experiencing significant growth in its market share for reconstructive knees and hips in important regions, even with the difficulties in the overall economy.

Zimmer Biomet's OsseoFit Stemless Shoulder System has received FDA 510(k) approval. The company plans to introduce the system in the first quarter of 2025.

Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur has received FDA 510(k) approval. The company plans to introduce the system in the first quarter of 2025.

Zimmer Biomet has received approval from the FDA for the Oxford Cementless Partial Knee. This approval is a PMA Supplement.

WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a leading company in medical technology, has announced that the U.S. Food and Drug Administration (FDA) has approved their Premarket Approval Application (PMA) Supplement for the Oxford® Cementless Partial Knee.

Zimmer Biomet has received CE Mark Certification for its Persona Revision Knee System, which was successfully launched in the United States and other regions.

On November 18, 2024, Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a leading company in medical technology, announced that it has obtained the CE Mark for its Persona® Revision Knee System. This certification allows the product to be sold in European markets.

Zimmer Biomet anticipates that the ROSA and Persona Cementless Knee will quickly boost its presence in the robotics and cementless market to between 50% and 60%.